Skip to main content
Premium Trial:

Request an Annual Quote

Danaher Acquisition of Cepheid Clears Antitrust Requirements

NEW YORK (GenomeWeb) – Danaher's proposed $4 billion acquisition of Cepheid has cleared antitrust requirements, Cepheid announced today.

Specifically, the firm said antitrust clearances have been received or the required waiting periods have expired in the US, Germany, Austria, and South Africa. 

The acquisition was announced in September. As GenomeWeb has reported, Cepheid is expected to broaden Danaher's diagnostics portfolio and fast track its presence in the molecular diagnostics space.

Cepheid will hold a meeting of its shareholders on Nov. 4 to vote on the merger.